Clinical Trials for Skin Cancer

Paid Clinical Trials and Focus Groups by Category

All Categories ... by Medical Condition » ... Cancers » ... Skin Cancer

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Condition: Melanoma
Intervention: Biological: NY-ESO-1 protein; Poly-ICLC; Montanide
Sponsors: Bhardwaj, Nina, M.D.; Ludwig Institute for Cancer Research; Oncovir, Inc.
Not yet recruiting - verified March 2010
Vitamin C as an Anti-cancer Drug

Condition: Prostatic Neoplasms
Intervention: Drug: Ascorbic Acid (Vitamin C)
Sponsors: Copenhagen University Hospital at Herlev; Rigshospitalet, Denmark; University of Copenhagen
Not yet recruiting - verified March 2010
The Vitamin D Dose-Response Relationship

Condition: Vitamin D Status
Interventions: Radiation: UVB; Radiation: UVB; Radiation: UVB; Radiation: UVB
Sponsors: Bispebjerg Hospital; The Danish Medical Research Council
Completed - verified February 2010
Remission in Subjects With Crohn's Disease, Open Label Extension

Condition: Crohn's Disease
Intervention: Biological: Adalimumab
Sponsor: Abbott
Completed - verified February 2010
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Conditions: Bladder Cancer; Skin Cancers
Intervention:
Sponsors: Stanford University; National Institutes of Health (NIH); Providence Foundation
Recruiting - verified February 2010
Neo-adjuvant Abiraterone Drug/Drug Interaction Study

Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: LHRHa
Sponsors: M.D. Anderson Cancer Center; Cougar Biotechnology, Inc.
Recruiting - verified March 2010
Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin

Condition: Melanoma
Intervention:
Sponsor: University of Pittsburgh
Not yet recruiting - verified March 2010
A Trial Testing Professional and Peer-led Support Online Support Groups for Young Canadian Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Behavioral: online support group; Behavioral: online support group; Behavioral: home study support materials
Sponsors: British Columbia Cancer Agency; University of Calgary; McMaster University; University of British Columbia; Tom Baker Cancer Centre; CancerCare Manitoba
Not yet recruiting - verified November 2009
Phyllodes Tumor Partial Breast Radiation Study

Condition: Phyllodes Tumor
Intervention: Radiation: Partial breast radiation after lumpectomy
Sponsor: Dartmouth-Hitchcock Medical Center
Recruiting - verified March 2010
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer

Condition: Breast Cancer
Intervention: Other: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol
Sponsors: University Medical Centre Groningen; Dutch Cancer Society
Recruiting - verified March 2010
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Condition: Melanoma (Skin)
Interventions: Biological: HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine; Biological: HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine; Biological: autologous melanoma lysate-pulsed autologous dendritic cell vaccine; Biological: autologous melanoma lysate/tracer antigen KLH-pulsed autologous dendritic cell vaccine; Biological: dendritic cell-idiotype-keyhole limpet hemocyanin vaccine; Other: flow cytometry; Procedure: adjuvant therapy
Sponsor: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Recruiting - verified March 2010
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Condition: Lentigo Maligna
Intervention: Drug: Imiquimod
Sponsor: Medical University of Graz
Not yet recruiting - verified March 2010
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers

Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course

Conditions: Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms
Intervention: Behavioral: Psychosocial rehabilitation course
Sponsors: Danish Cancer Society; University Hospital Århus, Department of Surgery; University Hospital Århus, Urology Department; Regional Hospital Randers, Department of Colorectal Surgery; Regional Hospital Hørsholm, Department of Breast Surgery
Completed - verified March 2010
Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: pixantrone dimaleate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Digital Mammography for the Detection and Preoperative Staging of Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)
Sponsors: Memorial Sloan-Kettering Cancer Center; GE Healthcare
Recruiting - verified March 2010
Effect of a Natural Health Product on Urinary Estrogen Metabolites

Condition: Breast Cancer
Intervention: Dietary Supplement: Breast Health
Sponsor: Nutrasource Diagnostics Inc.
Recruiting - verified March 2010
Female Cancer Patients' Preference For Sexual Health Interventions

Conditions: Breast Cancer; Gynecologic Cancer
Intervention:
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Demonstrate Efficacy and Safety of CT-P6 and Herceptin With Paclitaxel in Patients With Metastatic Breast Cancer

Conditions: HER2 Positive; Metastatic Breast Cancer
Interventions: Drug: CT-P6; Drug: Herceptin; Drug: Paclitaxel
Sponsor: Celltrion
Not yet recruiting - verified March 2010
Estrogen for Triple Negative Breast Cancer

Condition: Female Breast Cancer
Intervention: Drug: Estradiol
Sponsor: University of Wisconsin, Madison
Recruiting - verified March 2010
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Drug: ixabepilone
Sponsor: City of Hope Medical Center
Not yet recruiting - verified March 2010
Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Condition: Hepatocellular Cancer
Intervention:
Sponsor: Sydney West Area Health Service
Recruiting - verified February 2010
Evaluate Safety and Efficacy,Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer

Conditions: HER2 Positive; Metastatic Breast Cancer
Interventions: Drug: CT-P6; Drug: Herceptin; Drug: Paclitaxel
Sponsor: Celltrion
Recruiting - verified March 2010
Study of XL147 or XL765 in Combination With Letrozole in Subjects With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: XL147; Drug: XL765; Drug: letrozole (Femara)
Sponsor: Exelixis
Not yet recruiting - verified March 2010
Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence

Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Not yet recruiting - verified March 2010
89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition

Condition: Breast Cancer
Intervention: Other: Imaging with 89Zr-trastuzumab PET
Sponsor: University Medical Centre Groningen
Recruiting - verified February 2010
Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)

Condition: Breast Cancer
Intervention: Other: 89Zr-bevacizumab PET imaging
Sponsor: University Medical Centre Groningen
Recruiting - verified February 2010
Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides

Condition: Lymphoma
Intervention: Radiation: TSEBT
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Evaluating the Age Extension of the NHS Breast Screening Programme

Condition: Breast Cancer Mortality
Intervention: Other: Invitation for breast screening
Sponsors: University of Oxford; Department of Health, United Kingdom
Not yet recruiting - verified March 2010
Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

Condition: Psoriasis
Interventions: Biological: ustekinumab; Biological: anti-TNF biologics; Biological: non-anti-TNF biologics; Drug: systemic non-biological treatments; Other: general population
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Not yet recruiting - verified March 2010
Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

Conditions: Rheumatoid Arthritis; Arthritis, Psoriatic; Ankylosing Spondylitis
Interventions: Biological: golimumab; Biological: anti-TNF biologics; Biological: non-anti-TNF biologics; Drug: systemic non-biological treatments; Other: general population
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Not yet recruiting - verified March 2010
A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer

Condition: Neutropenia in Breast Cancer
Interventions: Drug: Filgrastim (Eurofarma); Drug: Filgrastim (Granulokine, Amgen)
Sponsor: Eurofarma Laboratorios Ltda
Not yet recruiting - verified March 2010
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: University of Pittsburgh; National Center for Research Resources (NCRR)
Recruiting - verified March 2010
GARDASIL™ Vaccine Impact in Population Study

Condition: Human Papillomavirus Infections
Intervention:
Sponsors: Merck; Danish Cancer Society; Icelandic Cancer Society; The Cancer Registry of Norway; Karolinska Institutet
Active, not recruiting - verified February 2010
Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network

Condition: HIV-1 Infections
Intervention:
Sponsors: Merck; Kaiser Permanente
Active, not recruiting - verified February 2010
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

Condition: Verruca Vulgaris
Interventions: Drug: Liquid nitrogen and cantharidin; Drug: Liquid nitrogen and topical placebo
Sponsor: North Idaho Dermatology
Completed - verified March 2010
Letrozole in Treating Healthy Postmenopausal Women at High Risk for Breast Cancer

Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsors: University of Arizona; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination

Condition: Human Papillomavirus Infection
Interventions: Biological: Cervarix; Biological: Engerix-B
Sponsor: National Institute for Public Health and the Environment (RIVM)
Terminated - verified March 2010
Brain Metastasis in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Trastuzumab or Lapatinib
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms

Conditions: Breast Cancer; CYP2D6 Polymorphism
Intervention: Drug: Tamoxifen
Sponsor: Sydney West Area Health Service
Not yet recruiting - verified February 2010
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin; Drug: PF-01367338; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Pfizer
Recruiting - verified February 2010
Lymph Fluid and Blood Collection for Identification of Novel Biomarkers

Condition: Adenocarcinoma of the Breast
Intervention:
Sponsor: Indiana University
Not yet recruiting - verified February 2010
Pilot Study Using Molecular Profiling to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Intervention: Drug: (will be assigned based on molecular profile and RPMA)
Sponsors: TGen Drug Development Services; SideOut Foundation
Recruiting - verified February 2010
Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: ZD9393 (Zoladex); Drug: ZD9393 (Zoladex)
Sponsor: AstraZeneca
Not yet recruiting - verified February 2010
Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors

Condition: Breast Cancer
Intervention:
Sponsor: Park Nicollet Institute
Recruiting - verified February 2010
SciBase International Melanoma Pivotal Study

Condition: Malignant Melanoma
Intervention: Device: SciBase III Electrical Impedance Spectrometer
Sponsor: SciBase AB
Not yet recruiting - verified February 2010
Apremilast in the Treatment of Moderate to Severe Acne

Condition: Acne
Intervention: Drug: apremilast
Sponsors: The University of North Carolina, Chapel Hill; Celgene Corporation
Recruiting - verified February 2010
Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: Low-Level Laser Therapy
Sponsor: Northwestern University
Not yet recruiting - verified March 2010
GDC-0449 and RO4929097 in Treating Women With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Hedgehog antagonist GDC-0449; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis
Intervention:
Sponsor: Abbott
Recruiting - verified February 2010
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB

Condition: Breast Cancer
Interventions: Radiation: APBI (Dose Escalation); Device: Contura MLB Breast Brachytherapy Catheter
Sponsor: SenoRx, Inc.
Recruiting - verified February 2010
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib

Condition: Breast Cancer
Intervention: Drug: Paclitaxel,Gemcitabine,Sunitinib
Sponsors: National Cancer Center, Korea; Pfizer; CJ Cheiljedang Corporation
Recruiting - verified January 2009
A Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Hormone Therapy

Conditions: Breast Cancer; Bone Metastases
Intervention: Drug: Radium-223 chloride (Alpharadin)
Sponsor: Algeta ASA
Recruiting - verified March 2010
The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy

Conditions: Breast Cancer; Fatigue; Insomnia
Intervention: Procedure: Therapeutic Massage
Sponsors: Floyd Memorial Hospital and Health Services; Indiana University
Not yet recruiting - verified February 2010
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Condition: Triple Negative Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab; Drug: Capecitabine
Sponsor: ARCAGY/ GINECO GROUP
Not yet recruiting - verified February 2010
Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™

Condition: Human Papillomavirus Infection
Intervention:
Sponsor: Merck
Active, not recruiting - verified February 2010
Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene

Condition: Breast Cancer
Intervention: Drug: Letrozole
Sponsor: Korean Breast Cancer Study Group
Enrolling by invitation - verified February 2010
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women

Condition: Breast Cancer
Intervention:
Sponsor: Korean Breast Cancer Study Group
Recruiting - verified February 2010
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Conditions: Breast Cancer; Diagnostic Imaging
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsor: Bayer
Recruiting - verified March 2010
Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer

Conditions: Breast Cancer; Metastasis, Neoplasm
Interventions: Drug: docetaxel, cisplatin, esomeprazole; Drug: Docetaxel, cisplatin, esomeprazole; Drug: Docetaxel, cisplatin
Sponsors: Fudan University; Istituto Superiore di Sanita
Recruiting - verified February 2010
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Daiichi Sankyo Inc.
Not yet recruiting - verified March 2010
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer

Condition: Breast Neoplasm
Intervention: Drug: Epirubicin: Observational Study
Sponsor: Pfizer
Completed - verified March 2010
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Conditions: Metastatic Non Small Cell Lung Cancer; Metastatic Breast Cancer
Interventions: Drug: Pazopanib; Drug: Vinorelbine
Sponsors: Northwestern University; GlaxoSmithKline
Recruiting - verified February 2010
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

Conditions: Genital Warts; Perianal Warts
Interventions: Drug: Polyphenon E (Veregen) 15% ointment; Other: Green Tea Beverage with defined catechin content
Sponsors: MediGene; Charité Research Organisation
Recruiting - verified March 2010
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas

Conditions: Neoplasms; Lymphoma
Interventions: Drug: LMP 400; Drug: LMP 776
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression

Condition: Breast Cancer
Intervention: Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Ixabepilone + Carboplatin Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Carboplatin
Sponsor: US Oncology Research
Recruiting - verified February 2010
A Study of V503 in Females 12-26 Years of Age Who Have Previously Received GARDASIL™

Conditions: Cervical Cancers; Vulvar Cancers; Vaginal Cancers; Genital Warts; Human Papillomavirus (HPV) Infection
Interventions: Biological: V503; Biological: Comparator: Placebo to V503
Sponsor: Merck
Recruiting - verified March 2010
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Conditions: Advanced Nonhematological Malignancies; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Condition: Breast Cancer, Metastatic
Interventions: Drug: SAR240550 (BSI-201); Drug: Gemcitabine; Drug: Carboplatin
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Study of XL147 in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

Conditions: Breast Cancer; Breast Neoplasms
Interventions: Drug: XL147; Biological: trastuzumab; Drug: paclitaxel
Sponsor: Exelixis
Recruiting - verified February 2010
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Aromasin; Drug: Aromasin
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

Condition: Breast Cancer
Intervention: Drug: Duloxetine
Sponsors: University of Michigan Cancer Center; Eli Lilly and Company
Recruiting - verified February 2010
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

Condition: Advanced or Metastatic Solid Tumors
Intervention: Drug: NMS-1286937
Sponsor: Nerviano Medical Sciences
Recruiting - verified March 2010
Comparison of Five Treatments in Patients With Plantar Warts

Condition: Plantar Warts
Interventions: Drug: Salicylate ointment; Drug: Imiquimod; Drug: 5-Fluoro-Uracil; Drug: Cryotherapy; Drug: Occlusive dressings
Sponsors: Assistance Publique - Hôpitaux de Paris; Society of Dermatology and venerology
Recruiting - verified February 2010
Evaluating the Adequacy of Giro-Couch to Support Prone Breast Boost Irradiation Using IMRT Technique With IGRT.

Condition: Breast Cancer
Intervention: Device: Support Device for Prone radiation therapy (Giro-Couch)
Sponsor: Azimuth Therapy Ltd.
Not yet recruiting - verified November 2009
Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients

Conditions: Advanced Cancers; Melanoma
Intervention: Procedure: Tumor Interstitial Fluid Pressure (IFP) assessments
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Lapatinib in Combination With Vinorelbine

Conditions: Cancer; Neoplasms, Breast
Interventions: Drug: Lapatinib; Drug: Vinorelbine; Drug: Capecitabine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

Condition: Severe Nodular Acne
Intervention: Drug: CIP-Isotretinoin and Isotretinoin
Sponsor: Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

Conditions: Stage IV Breast Cancer; Recurrent Breast Cancer
Interventions: Drug: calcium gluconate; Drug: magnesium sulfate; Other: placebo; Other: quality-of-life assessment; Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsor: Mayo Clinic
Recruiting - verified February 2010
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Wyeth; Genentech
Recruiting - verified March 2010
Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers

Condition: Cancer
Interventions: Drug: Placebo; Drug: GSK2256098
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
High-Dose Methotrexate and Liposomal Cytarabine in Treating Patients With Central Nervous System (CNS) Metastases From Breast Cancer

Conditions: Stage IV Breast Cancer; Central Nervous System Involvement/Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
A Study of LY573636 in Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: LY573636
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Vaccine Therapy in Treating Women With Triple-Negative Breast Cancer

Conditions: Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine; Biological: poly ICLC; Biological: MUC1 peptide-poly-ICLC adjuvant vaccine; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified February 2010
Geriatric Group Psychoeducational Intervention for Elderly Patients With Cancer

Conditions: Breast Cancer; Prostate Cancer
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Cyclosporins; Drug: nab-paclitaxel
Sponsors: Northwestern University; Avon Foundation
Recruiting - verified February 2010
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

Condition: Human Papillomavirus Infection
Interventions: Biological: V503; Biological: Comparator: Menactra™ (Concomitant); Biological: Comparator: Adacel™ (concomitant); Biological: Comparator: Menactra™ (Non-Concomitant); Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor: Merck
Recruiting - verified March 2010
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Condition: Breast Cancer
Interventions: Drug: BIIB021; Drug: BIIB021; Drug: exemestane (Aromasin)
Sponsor: Biogen Idec
Recruiting - verified March 2010
A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer

Conditions: Advanced/Recurrent Breast Cancer; Endometrial Cancer; Ovarian Cancer
Intervention: Drug: Temsirolimus/PLD
Sponsor: Radboud University
Recruiting - verified March 2010
XERAD: A Study of Xeloda (Capecitabine) Plus Radiotherapy in Patients With Breast Cancer With Newly Diagnosed Brain Metastases

Condition: Breast Cancer
Interventions: Drug: capecitabine [Xeloda]; Radiation: WBRT; Drug: systemic therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Investigation of Genetic Determinants of Capecitabine Toxicity

Condition: Breast Cancer
Interventions: Other: Side-effect questionnaires; Other: research blood samples
Sponsors: University of Chicago; Translational Breast Cancer Reserach Consortium; National Institutes of Health (NIH)
Recruiting - verified February 2010
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: docetaxel; Drug: FEC: 5-Fluorouracil/epirubicin/cyclophosphamide; Drug: carboplatin; Drug: trastuzumab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsor: Pfizer
Recruiting - verified March 2010
Regulatory Tykerb PMS

Condition: Breast Cancer
Intervention: Drug: tykerb
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies

Conditions: Rectal Cancer; Breast Cancer; Lung Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; American Society of Clinical Oncology
Recruiting - verified March 2010
Alpha-Type 1 Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: androgen ablation + dendritic cell vaccine; Biological: androgen ablation plus dendritic cell vaccine
Sponsor: University of Pittsburgh
Recruiting - verified March 2010
DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: therapeutic dehydroepiandrosterone; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Effects of Internet Support for Cancer Patients

Condition: Breast Cancer
Interventions: Behavioral: Online patient-provider communication service; Behavioral: WebChoice ITCA
Sponsors: Rikshospitalet HF; South-Eastern Norway Regional Health Authority
Recruiting - verified March 2010
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients

Condition: Cutaneous T-Cell Lymphoma
Intervention: Dietary Supplement: Curcumin (Turmeric)
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting - verified February 2010
Autologous CD19-specific T Cells Infusion

Conditions: Lymphoma; B-Cell Lymphoma
Interventions: Procedure: Leukapheresis; Procedure: Stem Cell Transplant; Procedure: CD19-specific T Cell Infusion; Drug: IL-2; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting - verified February 2010
Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)

Condition: Breast Cancer
Interventions: Radiation: PET; Other: Laboratory Testing; Other: Safety Testing; Drug: F18-FFNP
Sponsor: Washington University School of Medicine
Recruiting - verified March 2010
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Conditions: Kidney Cancer; Head and Neck Cancer; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Esophageal Cancer; Gliomas
Intervention: Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2010
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: bevacizumab [Avastin]; Drug: capecitabine [Xeloda]; Drug: docetaxel
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Continuation Study of E7389 for Advanced or Relapsed Breast Cancer

Condition: Breast Cancer
Intervention: Drug: E7389
Sponsor: Eisai Limited
Active, not recruiting - verified February 2010
A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors

Conditions: Advanced Solid Tumors Documented to be HER2+; Breast Cancer
Interventions: Drug: MK2206; Drug: Comparator: MK2206; Biological: Comparator: trastuzumab; Drug: Comparator: lapatinib
Sponsor: Merck
Recruiting - verified March 2010
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy

Condition: Lumpectomy
Interventions: Device: PEAK PlasmaBlade; Procedure: Traditional Electrosurgery with scalpel
Sponsor: Peak Surgical, Inc.
Enrolling by invitation - verified March 2010
Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy

Condition: Breast Neoplasms
Intervention: Drug: Everolimus
Sponsor: Organisation for Oncology and Translational Research
Recruiting - verified March 2010
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Conditions: Melanoma; Skin Cancer
Interventions: Drug: MART-1: 26-35(27L) Peptide; Drug: Montanide ISA 51 VG; Drug: gp100:154-162 Peptide; Drug: PG 13/Faf2aB C 162D1 (anti- MART-1 F5 TCR); Drug: PG13-154-Ecll AIB (anti-gp100:154-162 TCR); Procedure: Radiation; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide; Genetic: Anti-gp 100:154 TCR PBL; Genetic: Anti-MART-1 F5 TCR PBL
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

Conditions: Breast Cancer; Hot Flashes; Menopausal Symptoms; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: flaxseed; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: paclitaxel; Drug: pertuzumab; Drug: trastuzumab-MCC-DM1
Sponsor: Genentech
Recruiting - verified February 2010
Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Procedure: Fine needle aspiration
Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified July 2009
Phase I Open Label Trial to Assess Safety of BIBW 2992 in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: Herceptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer; Bone Metastases in Subjects With Advanced Breast Cancer; Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Intervention: Drug: amg 162
Sponsor: Amgen
Enrolling by invitation - verified March 2010
A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2Positive Early Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: 5-fluorouracil; Drug: epirubicin; Drug: cyclophosphamide
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study With Health Educational Material on Health Promotion in Cancer Survivors

Conditions: Stomach Cancer; Colon Cancer; Thyroid Cancer; Breast Cancer
Intervention: Behavioral: Brochure of Secondary Cancer Screening
Sponsor: National Cancer Center, Korea
Active, not recruiting - verified September 2009
PEAK PlasmaBlade™ 4.0 vs. Traditional Electrosurgery in Mastectomy

Condition: Mastectomy
Interventions: Device: Scalpel and Traditional Electrosurgery; Device: PEAK PlasmaBlade
Sponsor: Peak Surgical, Inc.
Enrolling by invitation - verified March 2010
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Dietary Supplement: CAM nutritional therapy; Dietary Supplement: Lactobacillus rhamnosus GG
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Not yet recruiting - verified July 2009
Radiation Therapy in Treating Patients With Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: intracavitary balloon brachytherapy; Radiation: intraoperative radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Dinaciclib in Treating Patients With Stage IV Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: dinaciclib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Suspended - verified February 2010
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

Condition: Human Papillomavirus Infection
Interventions: Procedure: Blood sampling; Procedure: Cervico-vaginal secretion (CVS) samples
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; The Indiana University Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2010
Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

Condition: Tumors
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsor: Bayer
Recruiting - verified March 2010
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus BSI-201
Sponsor: BiPar Sciences
Active, not recruiting - verified February 2010
A Study of Trastuzumab-MCC-DM1 (T-DM1) in Combination With Docetaxel in Patients With Advanced Breast Cancer

Condition: HER2 Positive Breast Cancer
Interventions: Drug: docetaxel; Drug: trastuzumab-DM1 (T-DM1)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin

Conditions: Breast Cancer; Healthy Volunteer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study of Stimuvax® in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Endocrine-sensitive Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Stimuvax (L-BLP 25 or BLP25 liposome vaccine) and Hormonal Treatment; Biological: Placebo of Stimuvax (L-BLP 25 or BLP25 liposome vaccine) and Hormonal Treatment; Drug: cyclophosphamide; Drug: sodium chloride
Sponsor: EMD Serono
Recruiting - verified March 2010
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Conditions: Neoplasms; Unresectable and Progressive Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Automating Breast Radiation Therapy (RT)

Condition: Breast Cancer
Intervention: Procedure: Cone Beam CT
Sponsor: University Health Network, Toronto
Recruiting - verified February 2010
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Placebo; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Sarah Cannon Research Institute; Novartis
Recruiting - verified January 2010
Study Evaluating Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in ErbB-2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

Conditions: Breast Cancer; Glioma; Hepatocellular Cancer; Squamous Cell Lung Cancer; Pancreatic Cancer; Colon Cancer; Prostate Cancer
Intervention: Biological: Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Sponsor: Envita Medical Center, Inc.
Suspended - verified February 2010
Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer

Conditions: Breast Cancer; Invasive Breast Cancer
Intervention: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Fondation du cancer du sein du Québec
Recruiting - verified May 2009
Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer

Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Exemestane; Drug: Sutent (Sunitinib)
Sponsors: Baylor Breast Care Center; Pfizer
Recruiting - verified March 2010
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

Condition: Brain and Central Nervous System Tumors
Interventions: Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

Condition: Metastatic Breast Cancer
Intervention: Drug: doxorubicinhydrochloride, Lapatinib
Sponsors: Arbeitsgemeinschaft medikamentoese Tumortherapie; GlaxoSmithKline
Recruiting - verified March 2010
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

Conditions: Actinic Keratoses; Skin Neoplasms
Interventions: Drug: Aminolevulinic Acid; Other: Vehicle
Sponsor: DUSA Pharmaceuticals, Inc.
Recruiting - verified March 2010
Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

Condition: Breast Cancer
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified March 2010
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: proteomic profiling; Genetic: reverse transcriptase-polymerase chain reaction; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: medical chart review; Procedure: quality-of-life assessment
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Radiation: radiation therapy
Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting - verified February 2010
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: proteomic profiling; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2008
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients

Conditions: Pulmonary Fibrosis; Breast Cancer
Interventions: Drug: Tamoxifen; Radiation: Radiotherapy
Sponsors: Tata Memorial Hospital; Indian Council of Medical Research
Recruiting - verified May 2009
Intellectual Impairment in Women With Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: Cognitive Rehabilitation (open); Behavioral: Neurofeedback Training (randomized)
Sponsors: Stanford University; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Detection of Aggressive Breast Tumors Using Tc-99m-NC100692

Condition: Breast Cancer
Intervention:
Sponsors: Mayo Clinic; GE Healthcare
Recruiting - verified March 2010
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy

Conditions: Breast Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Small Cell Lung Cancer
Intervention:
Sponsor: Amgen
Recruiting - verified March 2010
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: ixabepilone
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Study Evaluating the Effects of Neratinib in Women With Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Recruiting - verified March 2010
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone in Post Menopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Flourescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma

Condition: Cancer
Intervention: Drug: Fluorescein
Sponsor: University of Utah
Recruiting - verified February 2010
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity; Cardiovascular Complications
Interventions: Biological: trastuzumab; Drug: doxorubicin hydrochloride; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Evaluation of Long-term Immunogenicity and Safety of a HPV Vaccine in Healthy Female Subjects

Condition: Human Papillomavirus Infection
Intervention: Procedure: Blood sampling
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)

Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Recruiting - verified March 2010
Broad Spectrum HPV Vaccine Dose Escalation Study

Conditions: Human Papilloma Virus; Cervical Cancer; Vulvar Cancer; Vaginal Cancer; Genital Warts
Interventions: Biological: V502; Biological: Comparator: V502 Dose formulation 2; Biological: Comparator: V502 Dose formulation 3; Biological: Comparator: V502 Dose formulation 4; Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
Sponsor: Merck
Completed - verified March 2010
Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

Condition: Cutaneous T-Cell Lymphoma
Intervention: Procedure: skin biopsy
Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified March 2010
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: docetaxel; Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study of Avastin (Bevacizumab) in Combination With Taxane-Based Chemotherapy as First Line Treatment in Patients With HER2 Negative Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: paclitaxel; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent

Condition: Advanced Renal Cell Carcinoma
Intervention: Other: Observational
Sponsor: Pfizer
Recruiting - verified March 2010
Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

Condition: Breast Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

Condition: Human Papillomavirus Infection
Interventions: Behavioral: Compliance; Behavioral: Message sidedness
Sponsors: Indiana University; Merck
Not yet recruiting - verified February 2010
Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy
Sponsors: University of Colorado, Denver; National Cancer Institute (NCI)
Recruiting - verified January 2009
Open Label Extension In Cancer Patients

Conditions: Breast Neoplasms; Prostatic Neoplasms
Intervention: Biological: Anti-NGF AB
Sponsor: Pfizer
Recruiting - verified March 2010
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Conditions: Skin Cancer; Melanoma; Metastatic Melanoma
Interventions: Drug: temozolomide; Drug: ABT-888; Drug: Placebo
Sponsor: Abbott
Active, not recruiting - verified March 2010
Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Drug: sorafenib tosylate; Drug: vinorelbine ditartrate
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 or Lapatinib or Trastuzumab

Condition: Breast Neoplasms
Interventions: Drug: trastuzumab; Drug: lapatinib; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

Condition: Tumors
Interventions: Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod; Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Sponsors: Bhardwaj, Nina, M.D.; Cancer Research Institute
Active, not recruiting - verified February 2010
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Baylor College of Medicine
Recruiting - verified March 2010
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.

Condition: Breast Cancer
Intervention: Device: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
Sponsor: U-Systems, Inc.
Recruiting - verified February 2010
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Conditions: Hematologic Malignancies; Graft vs Host Disease
Interventions: Procedure: reduced intensity, matched related donor stem cell transplant; Drug: tacrolimus (standard GVHD prophylaxis); Drug: mycophenolate (standard GVHD prophylaxis); Drug: vorinostat
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Condition: Triple Negative Breast Cancer
Intervention: Drug: gemcitabine plus carboplatin plus BSI-201
Sponsors: BiPar Sciences; Breast Cancer Research Foundation
Recruiting - verified March 2010
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Condition: Advanced or Metastatic ErbB2-overexpressing Breast Cancer
Intervention: Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: trastuzumab [Herceptin]; Drug: bevacizumab [Avastin]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Conditions: Breast Cancer; Breast Neoplasms; Breast Tumors; Cancer; Locally Recurrent and Metastatic Breast Cancer; Metastases; Metastatic Cancer; Oncology; Solid Tumors; Tumors
Interventions: Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab; Drug: AMG 386 3 mg/kg, Paclitaxel and Trastuzumab; Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib; Drug: AMG 386 3 mg/kg, Capecitabine and Lapatinib
Sponsor: Amgen
Recruiting - verified February 2010
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing a Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Drug: ondansetron hydrochloride; Other: survey administration; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Procedure: Echocardiograms; Procedure: Blood Test
Sponsors: M.D. Anderson Cancer Center; Massachusetts General Hospital
Recruiting - verified March 2010
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: trastuzumab (Herceptin®)
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Efficacy and Safety of RAD001 in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)

Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Conditions: Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
Interventions: Drug: Everolimus (RAD001); Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vaccine Therapy and Aldesleukin in Treating Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: aldesleukin; Biological: allogeneic large multivalent immunogen breast cancer vaccine; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy

Condition: Breast Neoplasms
Intervention: Other: Aromatase inhibitors
Sponsor: Pfizer
Recruiting - verified March 2010
Phase I/II AZD2281/Cisplatin in Neoadjuvant Treatment of Triple Negative Breast Cancer Patients

Conditions: Advanced Solid Tumors; Triple Negative Breast Cancer
Interventions: Drug: AZD2281; Drug: Cisplatin
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsor: Wyeth
Recruiting - verified February 2010
Personalized Treatment Selection for Dasatinib in Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2010
Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Abraxis BioScience Inc.; Genentech
Recruiting - verified February 2010
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

Condition: Breast Neoplasms
Intervention: Other: Aromasin
Sponsor: Pfizer
Recruiting - verified February 2010
Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy

Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: docetaxel
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Paclitaxel and Trastuzumab and/or Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Exemestane + Dasatinib; Drug: Exemestane + Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
The Performance of Patient Support Program in Early Stage Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom

Conditions: Bladder Cancer; Brain and Central Nervous System Tumors; Esophageal Cancer; Intraocular Melanoma; Kidney Cancer; Lymphoma; Melanoma (Skin); Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsor: Cancer Research UK
Recruiting - verified September 2008
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Lymphoma; Multiple Myeloma; Leukemia, Myelomonocytic, Chronic
Intervention: Drug: azacitidine
Sponsor: Celgene Corporation
Recruiting - verified March 2010
A Study of Dalotuzumab (MK0646) in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Comparator: Dalotuzumab (MK0646)
Sponsor: Merck
Completed - verified March 2010
A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck)

Conditions: Non-Small Cell Lung; Breast Cancer; Melanoma; Upper GI Tract Carcinoma; Colon Carcinoma; Renal Cell Carcinoma; Bladder Carcinoma; Prostate Cancer
Interventions: Biological: V935; Biological: V934 EP (3 doses) and V935 (2 doses); Biological: V934 EP (5 doses) + V935 (2 doses); Biological: V934 DNA EP (3 doses)
Sponsor: Merck
Active, not recruiting - verified February 2010
Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Condition: Advanced Breast Cancer
Interventions: Drug: Dasatinib + Fulvestrant; Drug: Fulvestrant
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Tarceva
Sponsors: M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified March 2010
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin; Biological: allogeneic large multivalent immunogen melanoma vaccine LP2307
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified June 2009
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716AM1)

Conditions: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965; Drug: Capecitabine; Drug: Erlotinib
Sponsor: Schering-Plough
Recruiting - verified March 2010
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease

Condition: Acute Graft Versus Host Disease
Intervention: Drug: Etanercept (Enbrel)
Sponsor: University of Michigan Cancer Center
Recruiting - verified February 2010
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

Condition: MAGE-A3-positive Unresectable and Progressive Metastatic Cutaneous Melanoma
Intervention: Biological: GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study for Safety and Effectiveness of IMCA12 by Itself or Combined With Antiestrogens to Treat Metastatic Breast Cancer in Patients Who Progressed on Antiestrogen Therapy

Condition: Metastatic Breast Cancer
Intervention: Biological: IMC-A12
Sponsor: ImClone LLC
Active, not recruiting - verified February 2010
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)

Condition: Breast Neoplasm
Intervention: Drug: Pegylated Lyposomal Doxorubicin
Sponsor: Schering-Plough
Recruiting - verified March 2010
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsor: Pfizer
Recruiting - verified March 2010
Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety

Condition: Breast Cancer
Interventions: Behavioral: questionnaires; Behavioral: audio recordings , questionnaires; Behavioral: audio recorded questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Imatinib Mesylate in Treating Patients With Sclerodermatous Chronic Graft-Versus-Host Disease

Condition: Cancer
Interventions: Drug: imatinib mesylate; Genetic: reverse transcriptase-polymerase chain reaction; Other: confocal microscopy; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: biopsy
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Letrozole; Drug: Letrozole
Sponsor: Boehringer Ingelheim Pharmaceuticals
Completed - verified March 2010
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed By Surgery

Condition: Melanoma (Skin)
Intervention: Drug: dasatinib
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer

Condition: Breast Cancer
Intervention: Biological: IMCL-1121B
Sponsor: ImClone LLC
Recruiting - verified March 2010
Pregabalin in Treating Women With Hot Flashes

Conditions: Breast Cancer; Hot Flashes
Interventions: Drug: pregabalin; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified February 2010
Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy

Condition: Breast Cancer
Intervention: Device: Conture Multi-Lumen Balloon
Sponsors: Virginia Commonwealth University; SenoRx, Inc.
Recruiting - verified February 2010
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Other: laboratory biomarker analysis; Procedure: colposcopic biopsy
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2010
Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3

Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: exemestane; Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsor: NCIC Clinical Trials Group
Recruiting - verified June 2009
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)(COMPLETED)

Condition: Breast Neoplasm
Interventions: Drug: Pegylated Liposomal Doxorubicin; Drug: Docetaxel; Drug: Trastuzumab
Sponsors: Schering-Plough; MDS Pharma Services
Completed - verified February 2010
Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)

Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Phase II Study of AZD2281 in Known BRCA or Recurrent High Grade Ovarian Cancer or Known BRCA/ Triple Neg Breast Cancer

Conditions: Ovarian Carcinoma; Breast Cancer
Intervention: Drug: AZD2281
Sponsors: AstraZeneca; British Columbia Cancer Agency
Active, not recruiting - verified March 2010
Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Drug: letrozole; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsor: Federation Nationale des Centres de Lutte Contre le Cancer
Recruiting - verified February 2010
Laboratory-Treated Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide, and Fludarabine in Treating Patients With Metastatic Melanoma

Condition: Melanoma (Skin)
Intervention: Biological: aldesleukin
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Self-Care for Lymphedema in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Other: questionnaire administration; Other: survey administration; Procedure: quality-of-life assessment
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Conditions: Hodgkin's Disease; Lymphoma
Intervention: Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim
Sponsors: Memorial Sloan-Kettering Cancer Center; Merck; Northwestern University; NorthShore University HealthSystem Research Institute; Weill Cornell Medical College
Recruiting - verified March 2010
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: gemcitabine hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Conditions: Breast Cancer; Cancer of the Breast; Neoplasms, Breast
Intervention: Drug: Estrace followed by anastrazole
Sponsors: Fox Chase Cancer Center; Kimmel Cancer Center (KCC)
Recruiting - verified March 2010
Study Of Sunitinib With Capecitabine In Breast Cancer

Condition: Advanced/Metastatic Breast Cancer
Interventions: Drug: Capecitabine; Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402

Conditions: Breast Cancer; Cognitive/Functional Effects; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Australian New Zealand Breast Cancer Trials Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

Conditions: Beta Thalassemia Major; Congenital Anemias
Intervention: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Procedure: CBCT Scan; Procedure: OBI KV Imaging
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
IRS Proteins and Trastuzumab Resistance

Condition: Breast Cancer
Intervention:
Sponsor: University of Massachusetts
Recruiting - verified March 2010
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies

Condition: Advanced Malignancies
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Other: flow cytometry; Other: laboratory biomarker analysis; Other: medical chart review
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified January 2010
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Conditions: Multiple Myeloma; Primary Amyloidosis
Interventions: Drug: Melphalan; Procedure: Stem Cell Infusion; Behavioral: Questionnaires; Drug: Granulocyte-colony stimulating factor (G-CSF); Procedure: Apheresis
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Axillary Reverse Mapping for Invasive Carcinoma of the Breast

Condition: Breast Cancer
Intervention: Procedure: Axillary Reverse Mapping
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: MK-0752 and Docetaxel; Drug: MK-0752
Sponsor: University of Michigan Cancer Center
Active, not recruiting - verified March 2010
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: ABT-869; Drug: paclitaxel; Drug: Placebo for ABT-869
Sponsors: Abbott; Genentech
Active, not recruiting - verified January 2010
Phase II, 2nd Line Melanoma - RAND Monotherapy

Condition: Melanoma
Intervention: Drug: Anti-CD137 (4-1BB) (BMS-663513)
Sponsor: Bristol-Myers Squibb
Completed - verified January 2010
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Condition: Ovarian, Fallopian or Primary Peritoneal Cancer.
Intervention: Drug: Alemtuzumab
Sponsor: University of Michigan Cancer Center
Recruiting - verified March 2010
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin

Condition: Non-melanomatous Skin Cancer
Interventions: Drug: diclofenac sodium gel; Drug: eflornithine hydrochloride ointment
Sponsors: University of Arizona; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Primary UVB-311nm and Adalimumab in Psoriasis Patients

Condition: Psoriasis
Intervention: Radiation: UVB-311nm
Sponsor: Medical University of Graz
Recruiting - verified March 2010
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis

Condition: Psoriasis
Interventions: Radiation: UVB-311nm; Other: No treatment
Sponsor: Medical University of Graz
Recruiting - verified March 2010
Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: ixabepilone; Drug: ixabepilone+cetuximab
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Phase I Study of Ixabepilone + Lapatinib +/- Capecitabine to Treat HER2 Positive Locally Advanced or Metastatic Breast Cancer

Conditions: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: Ixabepilone + lapatinib; Drug: Ixabepilone + lapatinib + capecitabine
Sponsors: Bristol-Myers Squibb; GlaxoSmithKline
Active, not recruiting - verified December 2009
A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer; Breast Tumors; Metastatic Cancer
Interventions: Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant
Sponsor: Amgen
Active, not recruiting - verified March 2010
DAMES: Daughters And MothErS Against Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: Standardized Materials Group; Behavioral: Independent Tailored Intervention; Behavioral: Partner-Assisted Tailored Intervention
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)

Conditions: Breast Cancer; Metastasis, Neoplasm
Interventions: Drug: Vinorelbine and Capecitabine; Drug: Vinorelbine and Capecitabine
Sponsor: Fudan University
Active, not recruiting - verified February 2010
Cyclophosphamide and Fludarabine Followed By Autologous Gene-Modified Lymphocytes, Vaccine Therapy, and High-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: ALVAC-CEA vaccine; Biological: aldesleukin; Biological: autologous anti-gp100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes; Drug: cyclophosphamide; Drug: fludarabine phosphate
Sponsor: National Cancer Institute (NCI)
Recruiting - verified October 2008
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics

Condition: Breast Cancer
Interventions: Drug: Anastrozole; Dietary Supplement: flaxseed; Drug: Placebo
Sponsors: Roswell Park Cancer Institute; National Center for Complementary and Alternative Medicine (NCCAM); AstraZeneca
Recruiting - verified February 2010
Phase II Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-)

Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: Nab-paclitaxel; Drug: Trastuzumab (for HER2+); Drug: Bevacizumab
Sponsor: University of California, Irvine
Recruiting - verified March 2010
Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer

Condition: Breast Cancer
Intervention: Drug: E7389
Sponsor: Eisai Limited
Completed - verified February 2010
Six vs 12 Months of Transtuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Docetaxel; Drug: Trastuzumab; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: 5-fluoruracil; Drug: Granulocyte-colony stimulating growth factor; Drug: Trastuzumab
Sponsors: Hellenic Oncology Research Group; University Hospital of Crete
Recruiting - verified March 2010
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Iron Overload; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: deferasirox
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Active, not recruiting - verified August 2009
Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy

Condition: Breast Cancer
Intervention:
Sponsor: University of Michigan Cancer Center
Active, not recruiting - verified February 2010
Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery

Conditions: Breast Cancer; Breast Surgery; Breast Reconstruction; Breast Reduction; Breast Augmentation
Interventions: Behavioral: questionnaires; Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; McMaster University; University College, London; Dartmouth-Hitchcock Medical Center
Recruiting - verified February 2010
Temozolomide as a Prophylaxis Against Brain Recurrence in Patients With Metastatic Breast Cancer (Study P05225)

Conditions: Breast Neoplasm; Brain Neoplasm; Second Neoplasm
Intervention: Drug: Temozolomide
Sponsor: Schering-Plough
Recruiting - verified March 2010
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer (MBC)

Condition: Metastatic Breast Cancer
Intervention: Drug: Ixabepilone
Sponsors: Bristol-Myers Squibb; US Oncology Research
Active, not recruiting - verified August 2009
MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial

Conditions: Hormone Receptor Negative Breast Cancer; Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: Medroxyprogesterone progesterone acetate (MPA); Drug: Medroxyprogesterone Acetate with Cyclophosphamide plus Methotrexate
Sponsor: Indiana University
Active, not recruiting - verified March 2010
The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer

Conditions: Breast Cancer; Counseling
Intervention: Behavioral: focus group & questionaire
Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting - verified February 2010
A Study of Effectiveness of Trabectedin for the Treatment of Patient With Specific Subtypes of Metastatic Breast Cancer

Condition: Breast Tumors
Intervention: Drug: Trabectedin; ET 743; Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar S.A.
Recruiting - verified February 2010
Clinical Outcomes in Hereditary Cancer

Conditions: Breast Cancer; Pancreatic Cancer
Intervention: Other: Genotyping
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Breast MRI Spectroscopy

Condition: Suspicion of, or Known Breast Cancer
Intervention: Other: Radiology/MRI scan
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Safety and Efficacy Study of FLT Radiolabeled Imaging Agent With PET Scan in Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: 3'-Deoxy-3'-18F Fluorothymidine; Drug: 3'-Deoxy-3'-18F Fluorothymidine
Sponsor: Virginia Commonwealth University
Recruiting - verified February 2010
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA)

Condition: Metastatic Breast Cancer
Interventions: Drug: docetaxel; Drug: pertuzumab; Drug: placebo; Drug: trastuzumab
Sponsors: Genentech; Roche Pharma AG
Recruiting - verified March 2010
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Ixabepilone + Capecitabine
Sponsor: Bristol-Myers Squibb
Completed - verified December 2009
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: FEC; Drug: Paclitaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Docetaxel; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

Conditions: Anal Cancer; Precancerous Condition
Interventions: Drug: cidofovir; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Procedure: biopsy; Procedure: histopathologic examination
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Patient's Anastrozole Compliance to Therapy Programme

Condition: Breast Cancer
Intervention: Drug: Anastrozole
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Pertuzumab and Cetuximab in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Cetuximab

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: pertuzumab; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified December 2008
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Conditions: Early Breast Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Lapatinib; Drug: Trastuzumab; Drug: Endocrine
Sponsors: Baylor Breast Care Center; GlaxoSmithKline
Recruiting - verified February 2010
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048AM2)

Condition: Breast Neoplasm
Interventions: Drug: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab; Drug: PLD, cyclophosphamide, trastuzumab, paclitaxel
Sponsor: Schering-Plough
Active, not recruiting - verified March 2010
This is a Study of Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Ixabepilone; Drug: Docetaxel; Drug: Capecitabine
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified October 2009
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: Herceptin; Drug: docetaxel
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Etanercept Plus UVB-311nm Phototherapy in Psoriasis

Condition: Psoriasis
Interventions: Radiation: UVB-311nm radiation; Other: No treatment
Sponsor: Medical University of Graz
Recruiting - verified March 2010
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Conditions: Breast Cancer; Carcinoma of the Breast
Interventions: Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Genentech
Recruiting - verified March 2010
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: docetaxel; Drug: epirubicin; Drug: capecitabine
Sponsor: National Cancer Institute, Naples
Completed - verified February 2010
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)

Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Liver Safety Under Upfront Arimidex vs Tamoxifen

Condition: Breast Cancer
Interventions: Drug: Anastrozole; Drug: Tamoxifen
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Neuropathic Pain in Survivors of Breast Cancer

Condition: Breast Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; Pfizer
Active, not recruiting - verified February 2010
Effect of SBG in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Drug: SBG (Soluble beta-glucan)
Sponsor: Biotec Pharmacon ASA
Completed - verified February 2010
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Conditions: Non-hematologic Malignancies; Metastatic Melanoma; Breast Cancer; Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma
Interventions: Drug: ABT-888; Drug: Temozolomide
Sponsor: Abbott
Active, not recruiting - verified December 2009
Cancer Genetics CD-ROM for Hispanics

Condition: Breast Cancer
Interventions: Behavioral: Computer Program; Behavioral: Focus Group; Other: Written Materials
Sponsors: M.D. Anderson Cancer Center; National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH)
Recruiting - verified March 2010
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Etanercept Treatment in the Early Course of Polymyalgia Rheumatica

Condition: Polymyalgia Rheumatica
Interventions: Drug: Etanercept (Enbrel); Drug: Sodium chloride (placebo)
Sponsor: Bispebjerg Hospital
Completed - verified February 2010
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin

Conditions: Triple Negative Metastatic Breast Cancer; Advanced Ovarian Cancer; Carboplatin; Paclitaxel
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Carboplatin; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel; Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Paclitaxel + Carboplatin
Sponsors: AstraZeneca; KuDOS Pharmaceuticals Limited
Recruiting - verified February 2010
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Condition: Locally Recurrent and Metastatic Breast Cancer
Interventions: Drug: AMG 386 Placebo; Drug: AMG 386; Drug: Bevacizumab; Drug: AMG 386; Drug: AMG 386; Drug: Paclitaxel
Sponsor: Amgen
Active, not recruiting - verified February 2010
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors

Condition: Advanced Malignancies
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: erlotinib hydrochloride; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Spectral Diagnosis of Cutaneous Malignancy

Condition: Skin Cancer
Intervention: Device: Spectral Diagnosis Probe
Sponsors: M.D. Anderson Cancer Center; University of Texas
Recruiting - verified March 2010
Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: RAD001
Sponsors: M.D. Anderson Cancer Center; Novartis
Recruiting - verified March 2010
A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Condition: Chronic Idiopathic Thrombocytopenic Purpura
Interventions: Biological: Gammaplex, intravenous immunoglobulin; Biological: Gammaplex; Biological: Gammaplex
Sponsor: Bio Products Laboratory
Recruiting - verified March 2010
Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma

Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: LBH589
Sponsor: Novartis Pharmaceuticals
Completed - verified February 2010
Beclomethasone in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: beclomethasone dipropionate; Drug: methotrexate; Drug: tacrolimus; Other: placebo
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Condition: Breast Cancer
Interventions: Drug: Gemcitabine; Drug: Sorafenib; Drug: Placebo; Drug: Capecitabine
Sponsors: Accelerated Community Oncology Research Network; Onyx Pharmaceuticals
Recruiting - verified March 2010
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Erlotinib
Sponsors: University of Kansas; Genentech
Recruiting - verified March 2010
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone & Trastuzumab; Drug: Docetaxel & Trastuzumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified February 2010
Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients

Condition: Radiation Dermatitis
Interventions: Other: RadiaPlexRx Gel; Other: Aquaphor Gel
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

Condition: Breast Cancer
Intervention: Procedure: Phlebotomy
Sponsors: M.D. Anderson Cancer Center; Myriad Pharmaceuticals
Recruiting - verified March 2010
Effect of Increased Light Exposure on Fatigue in Breast Cancer

Condition: Breast Cancer
Interventions: Device: light box ( Litebook); Device: light box ( Litebook)
Sponsors: University of California, San Diego; California Breast Cancer Research Program
Completed - verified March 2010
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Taxane (docetaxel or paclitaxel)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Conditions: Bladder Cancer; Breast Cancer; Kidney Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: custirsen sodium; Drug: docetaxel; Other: pharmacological study
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Condition: Breast Neoplasms
Intervention: Drug: sunitinib
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Drug: tipifarnib; Procedure: axillary lymph node dissection; Procedure: conventional surgery
Sponsors: New York Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women

Conditions: Breast Cancer; Obesity; Weight Changes
Interventions: Behavioral: behavioral dietary intervention; Behavioral: exercise intervention; Dietary Supplement: dietary intervention; Other: educational intervention; Other: laboratory biomarker analysis; Other: preventative dietary intervention; Procedure: complementary or alternative medicine procedure; Procedure: evaluation of cancer risk factors; Procedure: immunoscintigraphy; Procedure: quality-of-life assessment; Procedure: radiomammography
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Active, not recruiting - verified July 2009
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Gemcitabine
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor Negative, Progesterone Receptor Negative, and HER2 Negative) Metastatic Breast Cancer

Condition: Breast Neoplasm
Interventions: Drug: cetuximab, cisplatin; Drug: Cisplatin
Sponsor: Merck KGaA
Active, not recruiting - verified February 2010
First Line Therapy for Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: ABI-007
Sponsor: Abraxis BioScience Inc.
Recruiting - verified January 2010
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Paclitaxel; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified November 2009
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

Conditions: Breast Cancer; Cervical Cancer; Prostate Cancer; Colorectal Cancer; Lung Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Patient Navigator (PN)
Sponsors: M.D. Anderson Cancer Center; Centers for Medicare and Medicaid Services
Recruiting - verified March 2010
A Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsor: Ferring Pharmaceuticals
Active, not recruiting - verified March 2010
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

Condition: Advanced Breast Cancer
Intervention: Drug: Dasatinib + Capecitabine
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified July 2009
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Conditions: Brain and Central Nervous System Tumors; Intraocular Melanoma; Lung Cancer; Melanoma (Skin); Metastatic Cancer; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma; Small Intestine Cancer
Interventions: Other: immunologic technique; Other: pharmacological study; Radiation: iodine I 131 monoclonal antibody 3F8
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified July 2009
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Taxane-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Condition: Breast Neoplasms
Interventions: Drug: EndoTAG-1 + paclitaxel; Drug: EndoTAG-1; Drug: Paclitaxel
Sponsor: MediGene
Active, not recruiting - verified March 2010
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Second line chemotherapy
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
A Phase I/II Study of HKI-272 in Combination With Paclitaxel in Subjects With Advanced Solid Tumors and Breast Cancer

Conditions: Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms
Intervention: Drug: HKI-272
Sponsor: Wyeth
Active, not recruiting - verified February 2010
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Second line chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Exemestane or Anastrozole in Treating Postmenopausal Women With Hormone Receptor-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Procedure: adjuvant therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group; International Breast Cancer Study Group
Active, not recruiting - verified March 2010
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Condition: Breast Cancer
Interventions: Drug: enzastaurin; Drug: placebo; Drug: capecitabine
Sponsor: Eli Lilly and Company
Terminated - verified February 2010
Vaccine Therapy and GM-CSF in Treating Patients With Stage III or Stage IV Breast Cancer or Ovarian Cancer

Conditions: Breast Cancer; Ovarian Cancer
Interventions: Biological: pNGVL3-hICD vaccine; Biological: sargramostim; Genetic: protein expression analysis; Other: flow cytometry; Other: immunoenzyme technique; Other: immunologic technique; Procedure: adjuvant therapy; Procedure: biopsy
Sponsors: University of Washington; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Brain Metastases In ErbB2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: lapatinib plus capecitabine; Drug: lapatinib plus topotecan
Sponsor: GlaxoSmithKline
Terminated - verified February 2010
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Sunitinib + Capecitabine; Drug: Capecitabine
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Thiotepa; Procedure: Stem Cell Transplant
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified March 2010
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

Conditions: Breast Cancer; Bone Metastases
Interventions: Drug: 153 Sm-EDTMP; Behavioral: Questionnaire; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; Cytogen Corporation
Active, not recruiting - verified February 2010
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Carcinoma, Renal Cell; Breast Neoplasms; Carcinoma, Islet Cell; Gastrointestinal Stromal Tumors
Intervention: Drug: sunitinib
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Docetaxel; Drug: Epirubicin; Drug: Epirubicin; Drug: Docetaxel
Sponsors: Hellenic Oncology Research Group; University Hospital of Crete
Recruiting - verified March 2010
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: fulvestrant
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Active, not recruiting - verified January 2009
Individualized Risk-Based Education in Promoting Breast Cancer Screening in Healthy Women

Condition: Breast Cancer
Interventions: Other: counseling intervention; Other: educational intervention; Procedure: evaluation of cancer risk factors; Other: Breast Cancer Risk Assessment at Baseline
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

Condition: Breast Cancer
Interventions: Drug: fluvastatin sodium; Other: clinical observation
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Vitamin D Deficiency and Muscle Pain and/or Joint Pain in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage III Breast Cancer

Conditions: Breast Cancer; Pain
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: letrozole; Procedure: adjuvant therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Active, not recruiting - verified July 2009
HOBOE: A Study of Hormonal Adjuvant Treatment Effect on Bone Mineral Density in Early Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: tamoxifen; Drug: triptorelin; Drug: letrozole; Drug: zoledronic acid
Sponsors: National Cancer Institute, Naples; Second University of Naples
Recruiting - verified February 2010
Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Conditions: Breast Cancer; Metastatic Cancer
Intervention: Drug: dasatinib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Condition: Melanoma (Skin)
Interventions: Drug: carboplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Genetic: protein expression analysis; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2009
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Trial of Acupuncture for Reduction of Post-Colectomy Ileus

Conditions: Postoperative Ileus; Colon Cancer; Pain, Postoperative; Postoperative Nausea and Vomiting
Interventions: Other: Acupuncture; Other: Sham Acupuncture
Sponsors: Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Active, not recruiting - verified February 2010
APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: Accelerated partial breast irradiation; Radiation: External beam whole breast irradiation
Sponsor: University of Erlangen-Nürnberg Medical School
Active, not recruiting - verified February 2010
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: ABI-007 plus Bevacizumab; Drug: Bevacizumab
Sponsor: Abraxis BioScience Inc.
Active, not recruiting - verified October 2009
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Sunitinib malate; Drug: Taxotere
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: mass spectrometry; Other: pharmacological study; Procedure: biopsy
Sponsors: Cancer Therapy and Research Center, Texas; National Cancer Institute (NCI)
Active, not recruiting - verified August 2008
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy

Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Naltrexone in Treating Women With Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

Condition: Breast Cancer
Interventions: Drug: naltrexone hydrochloride; Procedure: computed tomography; Procedure: positron emission tomography; Radiation: fludeoxyglucose F 18
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Condition: Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Condition: Breast Cancer
Interventions: Drug: Herceptin; Drug: Sunitinib; Drug: Taxotere
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: CP-751,871 + exemestane; Drug: exemestane
Sponsors: Pfizer; Massachusetts General Hospital
Recruiting - verified March 2010
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Conditions: Breast Cancer; Metastasis
Intervention: Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Completed - verified April 2009
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Ixabepilone; Drug: Bevacizumab; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Bevacizumab
Sponsor: Bristol-Myers Squibb
Completed - verified December 2009
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer

Condition: Breast Cancer
Interventions: Other: laboratory biomarker analysis; Procedure: needle biopsy; Procedure: positron emission tomography; Procedure: radionuclide imaging; Radiation: F-18 16 alpha-fluoroestradiol; Radiation: fludeoxyglucose F 18
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

Condition: Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein; Other: flow cytometry; Other: immunohistochemistry staining method; Other: immunological diagnostic method; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Conditions: Carcinoma, Renal Cell; Melanoma
Interventions: Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody; Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody; Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody; Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody; Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody; Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody; Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody; Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Sponsor: Genzyme
Completed - verified March 2010
Iressa Follow-up Trial

Conditions: Lung Cancer; Breast Cancer
Intervention: Drug: Gefitinib
Sponsor: AstraZeneca
Recruiting - verified March 2010
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Conditions: Breast Neoplasms; Breast Tumors; Breast Cancer; Locally Recurrent and Metastatic Breast Cancer
Interventions: Drug: AMG 706 placebo; Drug: Bevacizumab; Drug: AMG 706
Sponsor: Amgen
Active, not recruiting - verified February 2010
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Anastrozole
Sponsor: AstraZeneca
Completed - verified March 2010
Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Capecitabine
Sponsors: University of Chicago; Breast Cancer Research Foundation; Roche Pharma AG
Active, not recruiting - verified February 2010
Studying Normal Breast Tissue and Cancer Risk

Condition: Breast Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2010
Feasibility Study for Prospective Diet and Lifestyle Cohorts in Delhi, Kerala, and Kolkota, India

Condition: Chronic Diseases
Intervention:
Sponsor: National Cancer Institute (NCI)
Completed - verified January 2010
Thyroid Dysfunction in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer Who Are Planning to Undergo Chemotherapy Compared to Thyroid Dysfunction in Healthy Volunteers

Conditions: Breast Cancer; Fatigue; Hypothyroidism
Interventions: Other: physiologic testing; Procedure: fatigue assessment and management; Procedure: management of therapy complications
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified November 2009
Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: gemcitabine; Drug: paclitaxel
Sponsor: Eli Lilly and Company
Completed - verified March 2010
A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: cetuximab; Drug: gemcitabine; Drug: gemcitabine; Drug: cetuximab
Sponsor: National Cancer Institute, Naples
Completed - verified February 2010
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

Conditions: Dermal Neurofibromas; Neurofibromatosis Type 1
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Active, not recruiting - verified October 2009
Doxorubicin Hydrochloride Liposome, Cyclophosphamide and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: pegylated liposomal doxorubicin hydrochloride
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: moxifloxacin hydrochloride
Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified July 2009
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pemetrexed; Drug: carboplatin; Drug: gemcitabine; Drug: vinorelbine
Sponsor: Eli Lilly and Company
Active, not recruiting - verified March 2010
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: imatinib mesylate
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2009
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Condition: Bone Metastases in Subjects With Advanced Breast Cancer
Interventions: Biological: Denosumab; Drug: Zoledronic Acid
Sponsors: Amgen; Daiichi Sankyo Inc.
Active, not recruiting - verified March 2010
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Completed - verified March 2010
Phase I Combination w/ Epirubicin

Condition: Metastatic Breast Cancer
Intervention: Drug: Ixabepilone and Epirubicin
Sponsor: Bristol-Myers Squibb
Completed - verified April 2009
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsor: GlaxoSmithKline
Completed - verified March 2010
An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

Condition: Stem Cell Mobilization
Intervention: Drug: AMD3100
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Conditions: Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Stage IV Breast Cancer
Interventions: Drug: lapatinib (GW572016); Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Swedish Medical Center; GlaxoSmithKline
Active, not recruiting - verified March 2010
Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.

Condition: Breast Cancer
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Docetaxel
Sponsors: Radboud University; Sanofi-Aventis; Amgen
Completed - verified March 2010
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance

Conditions: Breast Cancer; Cancer Survivor; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Sexuality and Reproductive Issues; Spiritual Concerns
Interventions: Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Vaccine Therapy With or Without Montanide ISA-51 and/or Imiquimod in Treating Patients With Melanoma That Has Been Removed By Surgery

Condition: Melanoma (Skin)
Interventions: Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Drug: imiquimod
Sponsor: National Cancer Institute (NCI)
Completed - verified July 2009
Combination Chemotherapy and Radiation Therapy Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: CD4+CD25+ regulatory T cells; Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified September 2009
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Doxil; Drug: Carboplatin; Drug: Herceptin
Sponsors: US Oncology Research; Ortho Biotech, Inc.; Tibotec Pharmaceutical Limited
Active, not recruiting - verified February 2010
Study Evaluating HKI-272 in Subjects With Advanced Breast Cancer

Conditions: Breast Neoplasms; Neoplasms
Intervention: Drug: HKI-272
Sponsor: Wyeth
Active, not recruiting - verified February 2010
Secondary Adjuvant Long Term Study With Arimidex

Condition: Breast Cancer
Intervention: Drug: Anastrozole
Sponsor: AstraZeneca
Recruiting - verified February 2010
Aprepitant, Granisetron, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Cyclophosphamide Before a Stem Cell Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nausea and Vomiting; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Drug: aprepitant; Drug: cyclophosphamide; Drug: dexamethasone; Drug: granisetron hydrochloride
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Active, not recruiting - verified June 2009
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

Condition: Head and Neck Cancer
Intervention: Drug: erlotinib hydrochloride
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified March 2010
Weekly vs. Every 2 Week vs. Every 3 Week Administration of Abraxane/Bevacizumab Combination in Metastatic Breast Cancer

Conditions: Breast Neoplasms; Neoplasm Metastasis
Intervention: Drug: ABI-007 (Abraxane) and Bevacizumab
Sponsor: Abraxis BioScience Inc.
Active, not recruiting - verified June 2008
RAPID: Randomized Trial of Accelerated Partial Breast Irradiation

Condition: Breast Cancer
Interventions: Radiation: 3D-CRT APBI; Radiation: WBI
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Canadian Breast Cancer Research Alliance
Recruiting - verified March 2010
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: exemestane; Drug: tamoxifen
Sponsor: Pfizer
Active, not recruiting - verified February 2010
Phase II Trial Comparing ABI-007 to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Araxane versus Taxotere
Sponsor: Abraxis BioScience Inc.
Active, not recruiting - verified August 2006
The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (Study P04445AM2)

Condition: Breast Cancer
Interventions: Drug: Pegylated liposomal doxorubicin (SCH 66336); Drug: Capecitabine
Sponsors: Schering-Plough; Essex Pharma GmbH
Active, not recruiting - verified March 2010
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole
Sponsors: American College of Surgeons; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Neulasta; Drug: Aranesp
Sponsor: Amgen
Completed - verified February 2010
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2007
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: custirsen sodium; Drug: docetaxel
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: everolimus
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

Conditions: DCIS; Early Invasive Breast Cancer
Intervention: Drug: Anastrozole
Sponsor: University of California, Irvine
Recruiting - verified March 2010
Biobank Skin Cancer: Storing Blood and Protein of Patients With Skin Cancer

Condition: Skin Cancer
Intervention:
Sponsors: Maastricht Radiation Oncology; Maastricht University Medical Center
Withdrawn - verified March 2010
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck

Condition: Skin Cancer
Interventions: Drug: Carboplatin; Radiation: Radiotherapy
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Princess Alexandra Hospital, Brisbane, Australia; The Royal Australian and New Zealand College of Radiologists; The Princess Alexandra Hospital Cancer Collaborative Group
Recruiting - verified September 2009
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: SU011248; Drug: Chemotherapy
Sponsor: Pfizer
Recruiting - verified March 2010
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

Conditions: Skin Cancer; Kidney Transplantation
Interventions: Drug: rapamycin; Drug: ciclosporine; Drug: tacrolimus
Sponsor: Hospices Civils de Lyon
Active, not recruiting - verified March 2010
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: Biopsy; Procedure: Serum Collection; Procedure: Urine Collection; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Capecitabine; Drug: Vinorelbine; Drug: Gemcitabine
Sponsors: Hoosier Oncology Group; Department of Defense; Indiana University School of Medicine; Walther Cancer Institute
Recruiting - verified February 2010
Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC

Condition: Metastatic Breast Cancer (MBC)
Interventions: Drug: gemcitabine; Drug: docetaxel; Drug: paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Conditions: Mycosis Fungoides; Sezary Syndrome
Intervention: Drug: HuMax-CD4 (zanolimumab)
Sponsor: Genmab
Active, not recruiting - verified March 2010
Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial

Condition: Cancer
Interventions: Procedure: Acupuncture and questionnaires; Procedure: placebo acupuncture
Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting - verified February 2010
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

Condition: Breast Cancer
Intervention: Procedure: high dose chemo then auto hematopoietic cell transplant
Sponsor: Stanford University
Completed - verified February 2010
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Conditions: Hypereosinophilic Syndrome; Systemic Mastocytosis; Chronic Myelomonocytic Leukemia; Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Biobank Mammary Cancer: Storing Blood and Protein of Patients With Mammary Cancer

Conditions: Mamma Carcinoma; Cancer
Intervention:
Sponsors: Maastricht Radiation Oncology; Maastricht University Medical Center
Withdrawn - verified March 2010
Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

Condition: Metastatic Breast Cancer
Interventions: Drug: gemcitabine; Drug: gemcitabine
Sponsor: Eli Lilly and Company
Completed - verified March 2010
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line

Condition: Breast Cancer
Interventions: Drug: gemcitabine; Drug: paclitaxel; Drug: carboplatin; Drug: cisplatin
Sponsor: Eli Lilly and Company
Completed - verified February 2010
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

Conditions: Multiple Myeloma; Lymphocytic Leukemia, Chronic; Lymphoma, Low-Grade
Interventions: Procedure: Reduced intensity conditioning; Procedure: Rapid immunosuppressive taper; Procedure: Prophylactic donor leukocyte infusions
Sponsor: University of Michigan Cancer Center
Active, not recruiting - verified February 2010
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Conditions: Melanoma; Colonic Neoplasms; Breast Neoplasms
Intervention: Drug: PD-0325901
Sponsor: Pfizer
Terminated - verified March 2010
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: exemestane; Drug: anastrozole
Sponsor: Pfizer
Recruiting - verified February 2010
Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions

Conditions: Atopic Dermatitis; Psoriasis; Alopecia; Mycosis Fungoides; Urticaria; Dermatoses; Stretch Marks
Intervention: Procedure: UVA1 and UVB Irradiation
Sponsor: University of Michigan
Active, not recruiting - verified February 2010
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pegfilgrastim; Drug: cyclophosphamide; Drug: methotrexate; Drug: 5-fluorouracil
Sponsor: Amgen
Completed - verified February 2010
Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Campath-1H + FK506 and Methylprednisolone for GVHD

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Interventions: Biological: alemtuzumab; Drug: methylprednisolone; Drug: tacrolimus
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers

Conditions: Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); Hypereosinophilic Syndrome; Systemic Mastocytosis
Intervention: Drug: AMN107
Sponsor: Novartis Pharmaceuticals
Active, not recruiting - verified March 2010
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

Conditions: Lymphoma; Non-melanomatous Skin Cancer; Precancerous Condition
Intervention: Drug: silicon phthalocyanine 4
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer

Conditions: Advanced Breast Cancer; Other Solid Tumors
Interventions: Drug: MK0752, Notch Inhibitor; Drug: MK0752, Notch Inhibitor - 450 mg; Drug: MK0752, Notch Inhibitor - 3 days on, 4 off; Drug: MK0752, Notch Inhibitor - 1 day on, 6 off; Drug: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
Sponsor: Merck
Recruiting - verified March 2010
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Condition: Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Completed - verified February 2010
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Cyclosporine Implant for Ocular Graft-Versus-Host Disease

Condition: Graft vs Host Disease
Intervention: Drug: Subconjunctival Cyclosporine Implant
Sponsor: National Eye Institute (NEI)
Active, not recruiting - verified December 2009
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer

Conditions: Lung Cancer; Breast Cancer; Bladder Cancer; Ovarian Cancer; Pancreatic Cancer
Interventions: Drug: AMG 706; Biological: Panitumumab; Drug: Gemcitabine/Cisplatin
Sponsor: Amgen
Terminated - verified February 2010
Everolimus in Treating Patients With Stage IV Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: everolimus
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2007
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma

Conditions: Melanoma; Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody; Biological: MDX-1379 Melanoma Peptide Vaccine
Sponsor: Bristol-Myers Squibb
Completed - verified March 2010
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: ispinesib
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified March 2010
BMS-599626 in Patients With Advanced Solid Malignancies

Conditions: Cancer; Metastases
Intervention: Drug: panHer
Sponsor: Bristol-Myers Squibb
Completed - verified October 2008
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: pentostatin
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
An Investigational Study of Gardasil (V501) in Reducing the Incidence of Anogenital Warts in Young Men

Condition: Condylomata Acuminata
Interventions: Biological: (Gardasil) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Biological: Comparator: placebo (unspecified)
Sponsor: Merck
Active, not recruiting - verified March 2010
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Conditions: Breast Cancer; Low Bone Mineral Density; Osteopenia
Interventions: Drug: Placebo; Drug: AMG 162 / Denosumab
Sponsor: Amgen
Active, not recruiting - verified March 2010
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer

Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Vaccine Therapy in Treating Patients With Metastatic Melanoma

Condition: Melanoma (Skin)
Intervention: Biological: recombinant fowlpox-TRICOM vaccine
Sponsors: University of Chicago; National Cancer Institute (NCI)
Completed - verified August 2006
Exemestane in Treating Postmenopausal Women at High Risk for Invasive Breast Cancer

Conditions: Breast Cancer; Precancerous Condition
Intervention: Drug: exemestane
Sponsors: Lombardi Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsor: NCIC Clinical Trials Group
Recruiting - verified March 2010
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: capecitabine [Xeloda]; Drug: Taxotere
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: celecoxib; Drug: vinorelbine ditartrate
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: pentostatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Active, not recruiting - verified March 2008
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer
Interventions: Drug: Letrozole; Drug: Lapatinib (GW572016)
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Conditions: Melanoma (Skin); Metastatic Cancer
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2007
Harvesting Cells for Experimental Cancer Treatments

Condition: Neoplasms
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2009
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer

Conditions: Breast Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group; International Breast Cancer Study Group
Active, not recruiting - verified March 2010
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: docetaxel; Drug: epirubicin hydrochloride
Sponsor: NCIC Clinical Trials Group
Recruiting - verified February 2009
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Conditions: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Exemestane
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
Intervention: Drug: ravuconazole
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - verified July 2004
Vaccine Therapy In Treating Patients At High Risk For Recurrence Of Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2007
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: tipifarnib
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Completed - verified August 2005
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: perifosine
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified March 2010
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: docetaxel; Drug: erlotinib hydrochloride
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: adjuvant therapy; Procedure: conventional surgery; Radiation: intraoperative radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Condition: Melanoma (Skin)
Intervention: Biological: PEG-interferon alfa-2b
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

Conditions: Breast Cancer; Osteoporosis
Intervention: Drug: zoledronic acid
Sponsors: Herbert Irving Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified April 2007
EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

Conditions: Breast Cancer; Neurotoxicity
Intervention: Dietary Supplement: EGb761
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified February 2010
Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: magnetic resonance imaging; Procedure: radiomammography; Procedure: spectroscopy; Radiation: gadopentetate dimeglumine
Sponsors: American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified May 2007
Cyclophosphamide and Doxorubicin or Paclitaxel in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Biological: dendritic cell-MART-1 peptide vaccine
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI); National Institutes of Health (NIH)
Active, not recruiting - verified February 2010
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Tamoxifen; Drug: Exemestane
Sponsors: Pfizer; International Collaborative Cancer Group (ICCG)
Active, not recruiting - verified February 2010
A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Condition: Breast Cancer
Intervention: Drug: BMS-275291
Sponsor: Bristol-Myers Squibb
Terminated - verified August 2007
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: magnetic resonance imaging; Procedure: radiomammography; Procedure: ultrasound imaging; Radiation: gadopentetate dimeglumine
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Cell Lines From High-Risk Breast Tissue

Condition: Healthy
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified October 2009
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Procedure: adjuvant therapy
Sponsor: Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified March 2007
Phase II Bevacizumab + Tax In Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions

Condition: Kaposi's Sarcoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2009
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Biological: recombinant interleukin-12
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Completed - verified April 2004
Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Conditions: Breast Cancer; Head and Neck Cancer; Lymphoma; Metastatic Cancer; Non-melanomatous Skin Cancer; Sarcoma
Intervention: Drug: silicon phthalocyanine 4
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified March 2010
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Condition: Breast Cancer
Interventions: Drug: CMF regimen; Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: methotrexate; Procedure: adjuvant therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group; NCIC Clinical Trials Group
Completed - verified January 2007
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Conditions: Breast Cancer; Osteoporosis
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: cholecalciferol; Drug: calcium gluconate; Drug: zoledronic acid; Procedure: adjuvant therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Completed - verified March 2006
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Biological: aldesleukin; Biological: filgrastim; Biological: sargramostim; Biological: therapeutic autologous lymphocytes; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsor: Roger Williams Medical Center
Withdrawn - verified March 2010
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Melanoma (Skin); Ovarian Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboxyamidotriazole; Drug: paclitaxel
Sponsor: National Cancer Institute (NCI)
Completed - verified August 2006
Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin; Drug: cyclophosphamide; Drug: fludarabine phosphate
Sponsor: National Cancer Institute (NCI)
Completed - verified July 2009
Interleukin-2 and Interleukin-12 in Treating Patients With Refractory or Advanced Solid Tumors

Conditions: Breast Cancer; Kidney Cancer; Lung Cancer; Ovarian Cancer; Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: aldesleukin; Biological: recombinant interleukin-12
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2007
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: epoetin alfa; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel; Procedure: adjuvant therapy
Sponsors: NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified March 2010
Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: conventional surgery; Radiation: radiation therapy
Sponsor: European Organization for Research and Treatment of Cancer
Recruiting - verified July 2009
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Condition: Breast Cancer
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Drug: tamoxifen citrate; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Screening and Diagnostic Trial to Compare the Effectiveness of Two Types of Mammography in Detecting Breast Cancer in Women

Condition: Breast Cancer
Interventions: Procedure: breast imaging study; Procedure: comparison of screening methods; Procedure: radiomammography
Sponsors: American College of Radiology Imaging Network; National Cancer Institute (NCI)
Completed - verified December 2003
Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

Conditions: HIV Infection; Kaposi's Sarcoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 2009
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: pegylated interferon alfa; Procedure: adjuvant therapy
Sponsor: European Organization for Research and Treatment of Cancer
Active, not recruiting - verified October 2000
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: fludarabine phosphate; Procedure: peripheral blood stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: etoposide; Drug: ifosfamide; Drug: Mesna
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: paclitaxel; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer

Conditions: Kidney Cancer; Melanoma (Skin)
Interventions: Biological: aldesleukin; Drug: bryostatin 1
Sponsors: Virginia Commonwealth University; National Cancer Institute (NCI)
Completed - verified February 2010
Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Condition: Melanoma (Skin)
Intervention: Drug: alvocidib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); Radiation Therapy Oncology Group; Southwest Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); North Central Cancer Treatment Group
Active, not recruiting - verified March 2010
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: semaxanib; Procedure: conventional surgery; Radiation: radiation therapy; Drug: tamoxifen
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Extragonadal Germ Cell Tumor; Infection; Lung Cancer; Lymphoma; Ovarian Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: levofloxacin
Sponsor: Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified July 2002
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; Federation Nationale des Centres de Lutte Contre le Cancer; Danish Breast Cancer Cooperative Group
Active, not recruiting - verified March 2001
Photodynamic Therapy in Treating Patients With Skin Cancer

Conditions: Non-melanomatous Skin Cancer; Precancerous Condition
Intervention: Drug: aminolevulinic acid
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI)
Completed - verified March 2010
Peripheral Stem Cell Transplant Plus Monoclonal Antibody Therapy in Treating Patients With High-Risk Hematologic Cancer, Refractory Breast or Kidney Cancer, or Melanoma

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Melanoma (Skin); Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: alemtuzumab; Biological: filgrastim; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: in vitro-treated peripheral blood stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Duke University; National Cancer Institute (NCI)
Active, not recruiting - verified November 2006
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010
O(6)-Benzylguanine and Carmustine in Treating Patients With Stage I or Stage II Cutaneous T-cell Lymphoma

Condition: Lymphoma
Interventions: Drug: O6-benzylguanine; Drug: carmustine
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Study of Proteus Syndrome and Related Congenital Disorders

Conditions: Growth Disorder; Mental Retardation; Multiple Abnormalies
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2009
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Drug: CMF regimen; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: tamoxifen citrate; Procedure: autologous bone marrow transplantation; Procedure: surgical procedure; Radiation: radiation therapy
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Letrozole After Tamoxifen in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; International Breast Cancer Study Group; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Conditions: Anemia; Breast Cancer; Chronic Myeloproliferative Disorders; Drug/Agent Toxicity by Tissue/Organ; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: epoetin alfa; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified November 2006
Combination Chemotherapy and Peripheral Stem Cell Transplantation Followed by Interleukin-2 and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Biological: aldesleukin; Biological: sargramostim; Drug: busulfan; Drug: melphalan; Drug: tamoxifen citrate; Drug: thiotepa; Procedure: bone marrow ablation with stem cell support; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Completed - verified March 2010
Tamoxifen in Treating Women With High-Risk Breast Cancer

Condition: Breast Cancer
Interventions: Drug: CMF regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: methotrexate; Drug: tamoxifen citrate; Radiation: radiation therapy
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: octreotide acetate; Drug: tamoxifen citrate
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: mitoxantrone hydrochloride; Drug: tamoxifen citrate
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

Conditions: Breast Cancer; Neutropenia
Interventions: Biological: filgrastim; Drug: docetaxel; Drug: epirubicin hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010

Clinical Trials for Skin Cancer - Clinical Trials

Clinical Trials for Skin Cancer

Paid Clinical Trials and Focus Groups by Category

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials